Hormonal
TNF-α antagonism with etanercept increases the ratio of high molecular weight (HMW) adiponectin to total adiponectin without changing total adiponectin levels or body composition.
Etanercept improves metabolic health by shifting adiponectin toward its most active form (HMW), rather than just increasing total amounts. This suggests TNF-α blockade helps the body utilize existing adiponectin more effectively.
Etanercept also increased the ratio of high molecular weight adiponectin to total adiponectin (+22.1 ± 9.2% vs. placebo, P < 0.02)... In contrast, body composition, lipids, C-reactive protein, and IL-6 were unchanged after 6 months.
Why this rating
Supported by specific ELISA measurements and statistical significance in a controlled trial.
Source
TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome
Takara L. Stanley et al. · The Journal of Clinical Endocrinology & Metabolism · 2010
DOI 10.1210/jc.2010-1170
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →